Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label study of sebetralstat for hereditary angioedema attacks
NL-OMON60940Phase 3Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sebetralstat in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2), sponsored by KalVista Pharmaceuticals. Primary endpoints: Adverse events, Laboratory safety and 1 more. Started Nov 2022; status: completed.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on NL-OMON60940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60940.